Apyx Medical Corporation to Release First Quarter of Fiscal Year 2019 Financial Results on May 8, 2019
01 April 2019 - 10:30PM
Business Wire
Apyx Medical Corporation, formerly Bovie Medical
Corporation, (NASDAQ:APYX) (the “Company”), a maker of
medical devices and supplies and the developer of J-Plasma®, a
patented surgical product marketed and sold under the Renuvion®
Cosmetic Technology brand in the cosmetic surgery market, today
announced that financial results for the first quarter of fiscal
year 2019 will be released after the market closes on Wednesday,
May 8.
Management will host a conference call at 4:30 p.m. Eastern Time
on May 8 to discuss the results of the quarter and to host a
question and answer session. To listen to the call by phone,
interested parties may dial 844-507-6493 (or 647-253-8641 for
international callers) and provide access code 8252538.
Participants should ask for the Apyx Medical Corporation Call. A
live webcast of the call will be accessible via the Investor
Relations section of the Company’s website and at:
https://event.on24.com/wcc/r/1960685/EA5CE433FA4C050FACEFFFC1DF623FB1.
A telephonic replay will be available approximately two hours
after the end of the call through May 22, 2019. The replay can be
accessed by dialing 800-585-8367 for U.S. callers or 416-621-4642
for international callers and using the replay access code:
8252538. The webcast will be archived on the Investor Relations
section of the Company’s website.
About Apyx Medical
Corporation:
Apyx Medical Corporation (formerly Bovie Medical Corporation) is
an advanced energy technology company with a passion for elevating
people’s lives through innovative products in the cosmetic and
surgical markets. Known for its innovative Helium Plasma
Technology, Apyx is solely focused on bringing transformative
solutions to the physicians and patients it serves. The company’s
Helium Plasma Technology is marketed and sold as Renuvion® in the
cosmetic surgery market and J-Plasma® in the hospital surgical
market. Renuvion offers plastic surgeons, fascial plastic surgeons
and cosmetic physicians a unique ability to provide controlled heat
to the tissue to achieve their desired results. The J-Plasma system
allows surgeons to operate with a high level of precision and
virtually eliminating unintended tissue trauma. The Company also
leverages its deep expertise and decades of experience in unique
waveforms through original equipment manufacturing (OEM) agreements
with other medical device manufacturers. For further information
about the Company and its products, please refer to the Apyx
Medical Corporation website at www.ApyxMedical.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190401005033/en/
Investor Relations
Contact:Westwicke Partners on behalf of Apyx
Medical CorporationMike Piccinino,
CFAinvestor.relations@apyxmedical.com
Apyx Medical (NASDAQ:APYX)
Historical Stock Chart
From Apr 2024 to May 2024
Apyx Medical (NASDAQ:APYX)
Historical Stock Chart
From May 2023 to May 2024